drugset / Trial / NCT03392246
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Phase 2
Active not recruiting
25 enrolled
Dana-Farber Cancer Institute
National Comprehensive Cancer Network · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a combination of two targeted therapies as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The drugs involved in this study are: * Osimertinib (Tagrisso) * Selumetinib
Timeline
- Start
- 2018-01-31
- Primary completion
- 2026-06-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Osimertinib | Small molecule | — | Oral |
| Subject | Selumetinib | Small molecule | — | Oral |